How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

28,432 results for

Topical Corticosteroid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

28261. Prevention of corticosteroid-induced intraocular pressure elevation using ISV-205. Full Text available with Trip Pro

Prevention of corticosteroid-induced intraocular pressure elevation using ISV-205. To determine whether a topical ophthalmic diclofenac sodium formulation containing a proprietary polymeric drug delivery system (ISV-205), when dosed concomitantly with 1% prednisolone acetate, is effective in blocking the intraocular pressure (IOP) response in humans.This was a multicenter, prospective, double-masked, parallel, vehicle-controlled study. We included 136 first-degree relatives of subjects (...) % ISV-205 groups, respectively, which was significant between the 0.06% ISV-205 and vehicle groups (P =.05). Eight (17%) of the 46 subjects receiving vehicle terminated the study because of high IOPs, compared with 1 (2%) of the 45 subjects receiving 0.06% ISV-205 and 3 (7%) of the 45 subjects receiving 0.1% ISV-205 (P =.03). The number of subjects with a clinically important corticosteroid response (> or =10-mm Hg increase) was greater in the vehicle group (12 [28%] of 43 subjects) compared

2003 Archives of ophthalmology Controlled trial quality: uncertain

28262. A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. (Abstract)

A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. Several clinical trials have established the benefit of using a topical corticosteroid in conjunction with tazarotene gel in the treatment of plaque psoriasis. However, there is little information comparing the relative benefits of different corticosteroids, or different formulations of corticosteroids, when used adjunctively with tazarotene.This (...) study was designed to compare the clinical benefits achieved with each of six commonly prescribed high- or mid-high-potency corticosteroid creams and ointments applied in conjunction with tazarotene 0.1% gel in the treatment of patients with stable plaque psoriasis.A 12-week, multicenter, investigator-masked, randomized, parallel-group study was performed with more than 200 patients who were randomly assigned to regimens of tazarotene 0.1% gel alone, tazarotene plus a high-potency topical

2002 Journal of cutaneous medicine and surgery Controlled trial quality: uncertain

28263. Herbal creams used for atopic eczema in Birmingham, UK illegally contain potent corticosteroids. Full Text available with Trip Pro

Herbal creams used for atopic eczema in Birmingham, UK illegally contain potent corticosteroids. To determine whether "herbal creams" reported as being effective for the treatment of childhood atopic eczema contained corticosteroids.Patients attending the paediatric dermatology clinic at Birmingham Children's Hospital, April 2001 to March 2002, and who reported using "herbal creams" with good effect for atopic eczema were asked to submit the cream for analysis. Hydrocortisone, clobetasone (...) butyrate, betamethasone valerate, and clobetasol propionate were analysed by HPLC.Twenty four creams from 19 patients, median (interquartile range) age 3.82 (0.69-7.98) years were analysed. All five creams labelled Wau Wa and the two labelled Muijiza cream contained clobetasol propionate. Thirteen of 17 unnamed creams contained corticosteroids: clobetasol proprionate (n = 4), clobetasol proprionate + hydrocortisone (n = 1), betamethasone valerate (n = 2), clobetasone butyrate (n = 3

2003 Archives of Disease in Childhood

28264. Corticosteroid allergy in asthma. (Abstract)

and again on D10.Two patients in the symptomatic group reacted to corticosteroids in patch tests, one to betamethasone-17-valerate, Hc-17-B and budesonide, and the other to budesonide and Hc-17-B. The first patient suffered from widespread eczematous dermatitis when using beclomethasone. Fluticasone caused oropharyngeal irritation, hoarseness and shortness of breath. The second patient experienced a severe rash after the fourth budesonide inhalation. She had used various topical corticosteroids for her (...) Corticosteroid allergy in asthma. Glucocorticosteroids form the basis of therapy for asthma and other allergic diseases. However, they frequently cause delayed contact allergy and occasionally immediate allergy. The purpose of this study was to investigate the occurrence of corticosteroid allergy among patients with asthma and with some complaints caused by inhaled corticosteroids.Patch tests with corticosteroids were performed in 51 asthma patients with side-effects from inhalant

2003 Allergy

28265. Performance of a corticosteroid inhaler with a spacer fashioned from a plastic cold-drink bottle: effects of changing bottle volume. (Abstract)

Performance of a corticosteroid inhaler with a spacer fashioned from a plastic cold-drink bottle: effects of changing bottle volume. Some clinicians advocate using metered-dose inhaler (MDI) spacers prepared from common household bottles. We evaluated the in vitro aerosol characteristics of fluticasone from the MDI alone and through spacers fashioned from 237-, 500-, 1000-, and 1500-mL polyethylene terephlate plastic cold drink bottles using a cascade impactor. Ten 110-microg actuations (...) microg/actuation) was greater (p < 0.001) than the same MDI mated with any bottle spacer (range 1.5-3.5 microg/actuation). These data suggest that any of the bottle spacers tested would be an acceptable method to decrease the quantity of fluticasone that would deposit onto the oropharynx and thereby diminish the risk of topical adverse effects. Among the range of volumes tested, there was no relationship between spacer volume and respirable dose of fluticasone.

2003 Journal of Asthma

28266. Inhibitory activity of CX-659S, a novel diaminouracil derivative, against the rebound phenomenon following withdrawal of corticosteroid therapy for chronic contact hypersensitivity responses. (Abstract)

dermatitis (AD). CX-659S suppresses the expression of mRNA for interleukin (IL)-4 and IL-10 but not that for IFN-gamma, and inhibits serum IgE production in a chronic CHR model. Although topical corticosteroids have been widely utilized in steroid-responsive dermatoses such as AD, their chronic use may be associated with significant side effects. In addition, a rebound phenomenon often occurs after discontinuation of prolonged use of topical corticosteroids, with enhanced production of IgE and Th2 cell (...) Inhibitory activity of CX-659S, a novel diaminouracil derivative, against the rebound phenomenon following withdrawal of corticosteroid therapy for chronic contact hypersensitivity responses. CX-659S, a newly discovered anti-inflammatory compound, exerts inhibitory effects on chronic contact hypersensitivity responses (CHRs) induced by repeated application with picryl chloride (PC), which is known to mimic many, if not all, events occurring within lesional skin of patients with atopic

2003 International Archives of Allergy and Immunology

28267. Persistent and recurrent tinea corporis in children treated with combination antifungal/ corticosteroid agents. (Abstract)

Persistent and recurrent tinea corporis in children treated with combination antifungal/ corticosteroid agents. Combination antifungal/corticosteroid preparations are widely used by nondermatologists in the treatment of superficial fungal infections in patients of all ages. Over half of the prescriptions written for the most commonly used combination agent clotrimazole 1%/betamethasone diproprionate 0.05% cream (Lotrisone, Schering, Kenilworth, NJ) were prescribed for children younger than 4 (...) years old. Our pediatric dermatology division has recently encountered a series of children with recurrent or persistent tinea corporis, especially tinea faciei, treated initially with combination antifungal/corticosteroid cream.All children evaluated for tinea corporis in a university hospital pediatric dermatology clinic from January through June 2001 were identified from the clinic registry for a retrospective chart review. Response to therapy was confirmed by telephone survey and/or follow-up

2003 Pediatrics

28268. Corticosteroid treatment in nasal polyposis with a three-year follow-up period. (Abstract)

Corticosteroid treatment in nasal polyposis with a three-year follow-up period. The management of nasal polyposis is undoubtedly a controversial subject. The part played by surgery seems to be steadily growing, if the number of published reports dedicated to this approach is any yardstick. Although the medical treatment remains the undisputed therapeutic mainstay, trials dedicated to the long-term assessment of its overall efficacy are scarce.Retrospective medical record review.The aim (...) of the study is focused on the evaluation of a dual modality, topical and systemic, over a follow-up period of 3 years. In all, 100 patients were treated according to a standardized therapeutic protocol combining short-term oral administration of prednisolone and daily intranasal spray of beclomethasone.Over the follow-up period of 3 years, this dual modality proved to be successful in 85% of the patients; only 15% had to undergo surgery after its failure. The average symptom reduction reached

2003 Laryngoscope

28269. Study of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticosteroid Therapy Alone in Patients With Chronic Asthma (0476-386)

Study of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticosteroid Therapy Alone in Patients With Chronic Asthma (0476-386) Study of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticosteroid Therapy Alone in Patients With Chronic Asthma (0476-386) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticosteroid Therapy Alone in Patients With Chronic Asthma (0476-386) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

2008 Clinical Trials

28270. The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial (The LOCCS Trial)

The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial (The LOCCS Trial) The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00156819 Recruitment Status : Completed First Posted : September 12, 2005 Results First Posted : December 9, 2015 Last Update Posted : December 9, 2015

2005 Clinical Trials

28271. Influence of a Inhaled Corticosteroid Therapy Versus Corticosteroid + LABA Therapy on the FeNO of Asthmatic Children

with a combination therapy compared to those with a corticosteroid mono therapy. Condition or disease Allergic Asthma Study Design Go to Layout table for study information Study Type : Observational Estimated Enrollment : 27 participants Observational Model: Case-Crossover Time Perspective: Prospective Study Start Date : September 2005 Actual Primary Completion Date : June 2008 Actual Study Completion Date : October 2008 Resource links provided by the National Library of Medicine related topics: related topics (...) Influence of a Inhaled Corticosteroid Therapy Versus Corticosteroid + LABA Therapy on the FeNO of Asthmatic Children Influence of a Inhaled Corticosteroid Therapy Versus Corticosteroid + LABA Therapy on the FeNO of Asthmatic Children - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2007 Clinical Trials

28272. Twice-weekly topical corticosteroid therapy may reduce atopic dermatitis relapses. (Abstract)

-U.S. Gov't United States Arch Dermatol 0372433 0003-987X 0 Adrenal Cortex Hormones 0 Androstadienes 0 Emollients CUT2W21N7U Fluticasone AIM IM Administration, Topical Adolescent Adrenal Cortex Hormones administration & dosage Adult Aged Androstadienes administration & dosage Child Dermatitis, Atopic diagnosis drug therapy Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Emollients Female Fluticasone Follow-Up Studies Humans Male Middle Aged Risk Assessment (...) Twice-weekly topical corticosteroid therapy may reduce atopic dermatitis relapses. 15381558 2004 10 19 2015 11 19 0003-987X 140 9 2004 Sep Archives of dermatology Arch Dermatol Twice-weekly topical corticosteroid therapy may reduce atopic dermatitis relapses. 1151-2 Williams Hywel C HC Queen's Medical Center University Hospital NHS Trust, Nottingham, England. hywel.williams@nottingham.ac.uk eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial Research Support, Non

2004 Archives of Dermatology Controlled trial quality: uncertain

28273. Addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis. Full Text available with Trip Pro

Addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis. 16710605 2006 10 20 2018 12 01 0001-5555 86 3 2006 Acta dermato-venereologica Acta Derm. Venereol. Addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis. 281-2 Bovenschen H Jorn HJ Gerritsen Wil-Janne WJ de Jong Elke M G J EM van de Kerkhof Peter C M PC eng Letter Randomized Controlled Trial Sweden Acta Derm Venereol 0370310 0001-5555 0 Anti-Inflammatory Agents 0

2006 Acta Dermato-Venereologica Controlled trial quality: uncertain

28274. Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid

Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid (ARABUL) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00802243 Recruitment Status : Unknown Verified December 2008 by University Hospital, Limoges. Recruitment status was: Recruiting First Posted : December 4, 2008 Last Update

2008 Clinical Trials

28275. Combining Topical Corticosteroid and LCD Treatment for Localized Plaque Psoriasis

Combining Topical Corticosteroid and LCD Treatment for Localized Plaque Psoriasis Combining Topical Corticosteroid and LCD Treatment for Localized Plaque Psoriasis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Combining Topical Corticosteroid and LCD Treatment for Localized Plaque Psoriasis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00769184 Recruitment Status : Completed First Posted : October 9, 2008 Results First Posted : August 19, 2015 Last Update Posted : August 19, 2015 Sponsor

2008 Clinical Trials

28276. Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis

Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00121381 Recruitment Status : Completed First Posted : July 21, 2005 Last

2005 Clinical Trials

28277. The Sun Protection Effect and Efficacy in Treatment of Sunburn Using Topical Corticosteroids.

The Sun Protection Effect and Efficacy in Treatment of Sunburn Using Topical Corticosteroids. The Sun Protection Effect and Efficacy in Treatment of Sunburn Using Topical Corticosteroids. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. The Sun Protection Effect and Efficacy in Treatment of Sunburn Using Topical Corticosteroids. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00206882 Recruitment Status : Unknown Verified August 2005 by Bispebjerg Hospital. Recruitment status was: Recruiting First

2005 Clinical Trials

28278. A clinical study of the efficacy of topical corticosteroids on dry eye Full Text available with Trip Pro

A clinical study of the efficacy of topical corticosteroids on dry eye To evaluate the effect of topical corticosteroid for treatment of moderate or severe dry eye.Sixty eyes of 30 patients with moderate or severe dry eye, who were not sensitive to artificial tears, were treated with 0.1% fluorometholone eye drops. Subjective symptom and objective tests were used to evaluate the efficacy of treatment before and after application of 0.1% fluorometholone eye drops for 1 week and 1 month. Side (...) effects were also evaluated.After 1 week of treatment, subjective symptoms were improved in all dry eye patients; objective tests were improved in all dry eye patients 1 month after treatment, and the difference was significant.Topical corticosteroid drops can rapidly and effectively relieve the symptoms and signs of moderate or severe dry eye.

2006 Journal of Zhejiang University. Science. B

28279. Using corticosteroids during pregnancy. Are topical, inhaled, or systemic agents associated with risk? Full Text available with Trip Pro

Using corticosteroids during pregnancy. Are topical, inhaled, or systemic agents associated with risk? I am concerned about use of corticosteroids during pregnancy. Some of my women patients of reproductive age are using topical, inhaled, or oral preparations, and I am not sure what to advise.Both topical and systemic corticosteroids are used for a variety of autoimmune and inflammatory conditions. Results of first-trimester studies were inconclusive and underpowered. Recent meta-analyses (...) suggest a small but significant association between use of systemic corticosteroids during the first trimester and oral clefts. This is consistent with results of animal studies. No similar evidence exists for topical or inhaled corticosteroids, probably because of much lower systemic exposure.

2004 Canadian Family Physician

28280. A proof-of-concept study to assess the putative dose response to topical corticosteroid in persistent allergic rhinitis using adenosine monophosphate challenge. Full Text available with Trip Pro

A proof-of-concept study to assess the putative dose response to topical corticosteroid in persistent allergic rhinitis using adenosine monophosphate challenge. The aim of this proof-of-concept study was to assess whether nasal adenosine monophosphate (AMP) challenge may be used to quantify dose response to topical fluticasone propionate (FP) in persistent allergic rhinitis (PER).Eligible subjects with PER entered a randomized double-blind crossover study of 2 weeks of intranasal FP at 100 (...) % (95% confidence interval -7.1 to 9.0, P=NS) by FP 100 microg, and 12.9% (4.8-20.9, P=0.009) by FP 400 microg. The 400-100 microg difference was 12.0% U (2.6-21.3, P=0.049). None of the other outcomes were responsive enough to detect any significant treatment effects. The standardized response means to FP 400 microg were 81% for AMP challenge, 54% for domiciliary PNIF, 53% for miniRQLQ, 24% for symptom scores and 18% for nasal nitric oxide. No adrenal suppression was detected at either dose.FP

2007 Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology Controlled trial quality: predicted high

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>